Evidence mapPaperPMID 41315419Full record

ArticleSchizophrenia (Heidelberg, Germany)2025

Distinct microRNA profiles in neuron-derived extracellular vesicles between recent-onset and chronic-phase schizophrenia.

Yasufumi Tomita, Kazuya Toriumi, Mitsuhiro Miyashita, Kazuhiro Suzuki, Hideya Kawaji, Masanari Itokawa, Makoto Arai

Abstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasufumi TomitaSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kazuya ToriumiSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. toriumi-kz@igakuken.or.jp.ORCID http://orcid.org/0000-0002-8593-3269
Mitsuhiro MiyashitaSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7798-1834
Kazuhiro SuzukiSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0038-4329
Hideya KawajiResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0575-0308
Masanari ItokawaSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Makoto AraiSchizophrenia Research Project, Department of Clinical Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3400-9815

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 22K07609MEXT | Japan Society for the Promotion of Science (JSPS) 23K27535MEXT | Japan Society for the Promotion of Science (JSPS) 24K18719MEXT | Japan Society for the Promotion of Science (JSPS) 25K02595MEXT | Japan Society for the Promotion of Science (JSPS) JP22J22871
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are critical regulators of neurodevelopment and are implicated in the pathogenesis of schizophrenia. Schizophrenia is increasingly recognized as a neurodevelopmental disorder, with most cases emerging during late adolescence and early adulthood, which is a critical period of brain maturation. However, the study of miRNAs during this phase has been limited by the challenges of postmortem brain analysis. Neuron-derived extracellular vesicles (NEVs) have recently been proposed for investigating brain-derived molecular profiles. In this study, NEVs were enriched from plasma using the L1CAM antibody in patients with recent-onset schizophrenia (ROS) within 5 years of onsets and chronic-phase schizophrenia (CS). The miRNA profiles of these NEVs in patients with ROS and CS were compared with those of age-and sex-matched healthy controls. Differential expression analysis revealed miRNA changes specific to the recent-onset phase as well as possible pathophysiological mechanisms transitioning from the recent-onset to the chronic phases. These findings provide novel insights into the role of miRNAs in neurodevelopmental abnormalities associated with schizophrenia onset. This study highlights the utility of NEVs as a tool for accessing brain-derived miRNA profiles and diagnostic biomarkers and underscores the importance of an onset period as a critical window for understanding the molecular underpinnings of schizophrenia.

Identifiers

PMID41315419
PMCPMC12753667

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.